Molecular markers as prognostic factors for local recurrence and radioresistance in head and neck squamous cell carcinoma
Benjamin D. Smith B.A.
Yale University School of Medicine, Department of Therapeutic Radiology, New Haven, Connecticut
Search for more papers by this authorCorresponding Author
Bruce G. Haffty M.D.
Yale University School of Medicine, Department of Therapeutic Radiology, New Haven, Connecticut
Department of Therapeutic Radiology, P.O. Box 208040, Yale University School of Medicine, New Haven, CT 06520-8040Search for more papers by this authorBenjamin D. Smith B.A.
Yale University School of Medicine, Department of Therapeutic Radiology, New Haven, Connecticut
Search for more papers by this authorCorresponding Author
Bruce G. Haffty M.D.
Yale University School of Medicine, Department of Therapeutic Radiology, New Haven, Connecticut
Department of Therapeutic Radiology, P.O. Box 208040, Yale University School of Medicine, New Haven, CT 06520-8040Search for more papers by this authorAbstract
Squamous cell carcinoma of the head and neck affects more than 500,000 people worldwide each year. Local–regional recurrence of disease is a common and challenging oncological problem in patients affected by this disease. Identification of risk factors for local relapse after appropriate local therapy with surgery, radiation, or combination therapy remains an active area of clinical research. The recent development of novel molecular markers has resulted in numerous studies evaluating the prognostic significance and potential clinical utility of these markers in identifying patients at risk for local–regional relapse. This article reviews recent studies evaluating molecular markers, including p53, angiogenesis-related markers, cyclin D1, epidermal growth factor receptor, loss of heterozygosity, DNA ploidy, and cell kinetic markers. The potential clinical utility of these markers and future directions along this avenue of investigation are discussed. Radiat. Oncol. Invest. 7:125–144, 1999. © 1999 Wiley-Liss, Inc.
REFERENCES
- 1Parkin DM, Laars E, Muir CS. Estimates of the worldwide frequency of sixteen major cancers in 1980. Int J Cancer 1988; 41: 184–197. Medline
- 2Vokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer. N Engl J Med 1993; 328: 184–194. Medline
- 3Swango PA. Cancers of the oral cavity and pharynx in the United States: an epidemiologic overview. J Public Health Dent 1996; 56: 309–318. Medline
- 4Haffty BG. Concurrent chemoradiation in the treatment of head and neck cancer. Hematol Oncol Clin North Am (in press).
- 5Brizel DM, Albers ME Fisher SR, Scher RL, Richtmeier WJ, Hars V, George SL, Huang AT, Prosnitz LR. Hyperfractionated irradiation with or without concurrent chemotherapy of locally advanced head and neck cancer. N Engl J Med 1998; 338: 1798–1803. Medline
- 6Overgaard J. Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors. Oncol Res 1994; 6: 509–518. Medline
- 7Haffty B,Son YH, Papac R, Sasaki CT, Weissberg JB, Fischer D, Rockwell S, Sartorelli AC, Fischer JJ. Chemotherapy as an adjunct to radiation in the treatment of squamous cell carcinoma of the head and neck: results of the Yale mitomycin randomized trials. J Clin Oncol 1997; 15: 268–276. Medline
- 8Rockwell S. Oxygen delivery: implications for the biology and therapy of solid tumors. Oncol Res 1997; 9: 383–390. Medline
- 9Horiot JC, Bontemps P, van den Bogaert W, Le Fur R, van den Weijngaert D, Bolla M, Bernier J, Lusinchi A, Stuschke M, Lopez-Torrecilla J, Begg AC, Pierart M, Collette L. Accelerated Fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial. Radiother Oncol 1997; 44: 111–121. Medline
- 10Munro AJ. An overview of randomised controlled trials of adjuvant chemotherapy in head and neck cancer. Br J Cancer 1995; 71: 83–91. Medline
- 11Mauceri HJ, Hann NN, Beckett MA, Gosrski DH, Staba MJ, Stellato KA Bigelo K, Heimann R, Gately S, Dhanabal M, Soff GA, Sukhatme VP, Kufe DW, Weichselbaum RR. Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature 1998; 394: 287–291. Medline
- 12Vokes EE, Athanasiadia I. Chemotherapy for squamous cell carcinoma of the head and neck: the future is now. Ann Oncol 1996; 7: 15–29.
- 13Brown JM, Siim BG. Hypoxia-specific cytotoxins in cancer therapy. Semin Radiat Oncol 1996; 6: 22–36.
- 14Forastiere AA, Urba SG. Single-agent paclitaxel plus ifosfamide in the treatment of head and neck cancer. Semin Oncol 1995; 22: 24–27.
- 15Lane DP. p53, guardian of the genome. Nature 1992; 358: 15–16. Medline
- 16Lane DP. The regulation of p53 function: Steiner Award lecture. Int J Cancer 1994; 57: 623–627. Medline
- 17Hunter T. Braking the cycle. Cell 1993; 75: 839–841. Medline
- 18Chang EH, Jang YJ, Hao Z, Murphy G, Rait A, Fee WE Jr, Sussman HH, Ryan P, Chiang Y, Pirollo KF. Restoration of the G1 checkpoint and the apoptotic pathway mediated by wild-type p53 sensitizes squamous cell carcinoma of the head and neck to radiotherapy. Arch Otolaryngol Head Neck Surg 1997; 123: 507–512. Medline
- 19Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 1991; 352: 345–347. Medline
- 20Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML, Wyllie AH. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 1993; 362: 849–852. Medline
- 21Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 1993; 362: 847–849. Medline
- 22Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74: 957–967. Medline
- 23Blank KR, Rudoltz MS, Kao GD, Muschell RJ, Mc-Kenna WG. The molecular regulation of apoptosis and implications for radiation oncology. Int J Radiat Biol 1997; 71: 455–466. Medline
- 24Pirollo KF, Hao Z, Rait A, Jang YJ, Fee WE Jr, Ryan P, Chiang Y, Chang EH. p53 mediated sensitization of squamous cell carcinoma of the head and neck to radiotherapy. Oncogene 1997; 14: 1735–1746. Medline
- 25Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, Giaccia AJ. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors. Nature 1996; 379: 88–91. Medline
- 26Jenkins JR, Rudge K, Chumakov P, Currie GA. The cellular oncogene p53 can be activated by mutagenesis. Nature 1985; 317: 816–818. Medline
- 27Iggo R, Gatter K, Bartek J, Lane D, Harris AL. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 1990; 335: 675–679. Medline
- 28Calzolari A, Chiarelli I, Bianchi S, Messerini L, Gallo O, Porfirio B, Mattiuz PL. Immunohistochemical vs molecular biology methods: complementary techniques for effective screening of p53 alterations in head and neck cancer. Am J Clin Pathol 1997; 107: 7–11. Medline
- 29Gleich LL, Li YQ, Biddinger PW, Gartside PS, Stambrook PJ, Pavelic ZP, Gluckman JL. The loss of heterozygosity in retinoblastoma and p53 suppressor genes as a prognostic indicator for head and neck cancer. Laryngoscope 1996; 106: 1378–1381. Medline
- 30Nogueira CP, Dolan RW, Gooey J, Byahatti S, Vaughan CW, Fuleihan NS, Grillone G, Baker E, Domanowski G. Inactivation of p53 and amplification of cyclin D1 correlate with clinical outcome in head and neck cancer. Laryngoscope 1998; 108: 345–350. Medline
- 31Wilson GD, Richman PI, Dische S, Sauders MI, Robinson B, Daley FM, Ross DA. p53 status of head and neck cancer: relation to biological characteristics and outcome of radiotherapy. Br J Cancer 1995; 71: 1248–1252. Medline
- 32Riva C, Lavieille JP, Reyt E, Brambilla E, Lunardi J, Brambilla C. Differential c-myc, c-jun, c-raf, and p53 expression in squamous cell carcinoma of the head and neck: implication in drug and radioresistance. Eur J Cancer B Oral Oncol 1995; 31B: 384–391. Medline
- 33Ahomadegbe JC, Barrois M, Fogel S, Le Bihan ML, Douc-Rasy S, Duvillard P, Armand JP, Riou G. High incidence of p53 alterations (mutation, deletion, overexpression) in head and neck primary tumors and metastases; absence of correlation with clinical outcome. Frequent protein overexpression in normal epithelium and in early non-invasive lesions. Oncogene 1995; 10: 1217–1227. Medline
- 34Shin DM, Lee JS, Lippman SM, Lee JJ, Tu ZN, Choi G, Heyne K, Shin HJC, Ro JY, Goepfert H, Hong WK, Hittelman WN. p53 expression: predicting recurrence and second primary tumors in head and neck squamous cell carcinoma. J Natl Cancer Inst 1996; 88: 519–529. Medline
- 35Chiba I, Shindoh M, Yasuda M, Yamazaki Y, Amemiya A, Sato Y, Fujinaga K, Notani K, Fukuda H. Mutations in the p53 gene and human papillomavirus infection as significant prognostic factors in squamous cell carcinomas of the oral cavity. Oncogene 1996; 12: 1663–1668. Medline
- 36Caminero MJ, Nunez F, Suarez C, Ablanedo P, Riera JR, Dominguez F. Detection of p53 protein in oropharyngeal carcinoma. Prognostic implications. Arch Otolaryngol Head Neck Surg 1996; 122: 769–772. Medline
- 37Kropveld A, Slootweg PJ, van Mansfeld AD, Blankenstein MA, Hordijk GJ. Radioresistance and p53 status of T2 laryngeal carcinoma. Analysis by immunohistochemistry and denaturing gradient gel electrophoresis. Cancer 1996; 78: 991–997.
Medline
10.1002/(SICI)1097-0142(19960901)78:5<991::AID-CNCR8>3.0.CO;2-F CAS PubMed Web of Science® Google Scholar
- 38Kokoska MS, Piccirillo JF, el-Mofty SK, Emami B, Haughey BH, Scholnick SB. Prognostic significance of clinical factors and p53 expression in patients with glottic carcinoma treated with radiation therapy. Cancer 1996; 78: 1693–1700.
Medline
10.1002/(SICI)1097-0142(19961015)78:8<1693::AID-CNCR9>3.0.CO;2-F CAS PubMed Web of Science® Google Scholar
- 39Raybaud-Diogene H, Fortin A, Morency R, Roy J, Monteil RA, Tetu B. Markers of radioresistance in squamous cell carcinomas of the head and neck: a clinicopathologic and immunohistochemical study. J Clin Oncol 1997; 15: 1030–1038. Medline
- 40Michalides RJ, van Veelen NM, Kristel PM, Hart AA, Loftus BM, Hilgers FJ, Balm AJ. Overexpression of cyclin D1 indicates a poor prognosis in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 1997; 123: 497–502. Medline
- 41Gluckman JL, Pavelic ZP, Welkoborosky HJ, Mann W, Stambrook P, Gleich L, Wilson K, Righi P, Portugal LG, McDonald J, Biddinger P, Steward D, Gartside P. Prognostic indicators for squamous cell carcinoma of the oral cavity: a clinicopathologic correlation. Laryngoscope 1997; 107: 1239–1244. Medline
- 42Hedge PU, Brenski AC, Caldarelli DD, Hutchinson J, Panje WR, Wood NB, Leurgans S, Preisler HD, Taylor SG 4th, Caldarelli L, Coon JS. Tumor angiogenesis and p53 mutations: prognosis in head and neck cancer. Arch Otolaryngol Head Neck Surg 1998; 124: 80–85. Medline
- 43Pai HH, Rochon L, Clark B, Black M, Shenouda G. Overexpression of p53 protein does not predict local-regional control or survival in patients with early-stage squamous cell carcinoma of the glottic larynx treated with radiotherapy. Int J Radiat Oncol Biol Phys 1998; 41: 37–42. Medline
- 44Overgaard J, Sorensen SB, Stausbol-Gron S, Hoyer M, Alsner J. TP53 mutation is an independent prognostic marker for poor outcome of radiotherapy in squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1998(Suppl); 42: 146.
10.1016/S0360-3016(98)80144-2 Google Scholar
- 45Narayana A, Vaughan AT, Kathuria S, Fisher SG, Walter SA, Reddy SP. p53 overexpression is associated with bulky tumor and poor local control in T1 glottic cancer. Int J Radiat Oncol Biol Phys 1998(Suppl); 42: 146.
10.1016/S0360-3016(98)80145-4 Google Scholar
- 46Veneroni S, Silvestrani R, Costa A, Salvatori P, Faranda A, Molinari R. Biological indicators of survival in patients treated by surgery for squamous cell carcinoma of the oral cavity and oropharynx. Oral Oncol 1997; 33: 408–413. Medline
- 47Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182–1186. Medline
- 48Folkman J. Tumor angiogenesis. Adv Cancer Res 1985; 43: 175–203. Medline
- 49Klagsbrun M, D'Amore PA. Regulators of angiogenesis. Annu Rev Physiol 1991; 53: 217–239. Medline
- 50Plate KH, Breier G, Weich HA, Risau W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 1992; 359: 845–848. Medline
- 51Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992; 359: 843–845. Medline
- 52Shweiki D, Neeman M, Itin A, Keshet E. Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: implications for tumor angiogenesis. Proc Natl Acad Sci USA 1995; 92: 768–772. Medline
- 53Hlatky L, Tsionou C, Hahnfeldt P, Coleman CN. Mammary fibroblasts may influence breast tumor angiogenesis via hypoxia-induced vascular endothelial growth factor up-regulation and protein expression. Cancer Res 1994; 54: 6083–6086. Medline
- 54Rockwell S, Knisely JP. Hypoxia and angiogenesis in experimental tumor models: therapeutic implications. EXS 1997; 79: 335–360. Medline
- 55Gatenby RA, Kessler HB, Rosenblum JS, Coia LR, Moldofsky PJ, Hartz WH, Broder GJ. Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. Int J Radiat Oncol Biol Phys 1988; 14: 831–838. Medline
- 56Denhart BC, Guidi AJ, Tognazzi K, Dvorak HF, Brown LF. Vascular permeability factor/vascular endothelial growth factor and its receptors in oral and laryngeal squamous cell carcinoma and dysplasia. Lab Invest 1997; 77: 659–664. Medline
- 57Moriyama M, Kumagai S, Kawashiri S, Kojima K, Kakihara K, Yamamoto E. Immunohistochemical study of tumour angiogenesis in oral squamous cell carcinoma. Oral Oncol 1997; 33: 369–374. Medline
- 58Salven P, Heikkila P, Anttonen A, Kajanti M, Joensuu H. Vascular endothelial growth factor in squamous cell head and neck carcinoma: expression and prognostic significance. Mod Pathol 1997; 10: 1128–1133. Medline
- 59Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis–correlation in invasive breast carcinoma. N Engl J Med 1991; 324: 1–8. Medline
- 60Williams JK, Carlson GW, Cohen C, Derose PB, Hunter S, Jurkiewicz MJ. Tumor angiogenesis as a prognostic factor in oral cavity tumors. Am J Surg 1994; 168: 373–380. Medline
- 61Alcalde RE, Shintani S, Yoshihama Y, Matsumura T. Cell proliferation and tumor angiogenesis in oral squamous cell carcinoma. Anticancer Res 1995; 15: 1417–1422. Medline
- 62Shpitzer T, Chaimoff M, Gal R, Stern Y, Feinmesser R, Segal K. Tumor angiogenesis as a prognostic factor in early oral tongue cancer. Arch Otolaryngol Head Neck Surg 1996; 122: 865–868. Medline
- 63Alcalde RE, Terakado N, Otsuki K, Matsumura T. Angiogenesis and expression of platelet-derived endothelial cell growth factor in oral squamous cell carcinoma. Oncology 1997; 54: 324–328. Medline
- 64Dray TG, Hardin NJ, Sofferman RA. Angiogenesis as a prognostic marker in early head and neck cancer. Ann Otol Rhinol Laryngol 1995; 104: 724–729. Medline
- 65Gleich LL, Biddinger PW, Pavelic ZP, Gluckman JL. Tumor angiogenesis in T1 oral cavity squamous cell carcinoma: role in predicting tumor aggressiveness. Head Neck 1996; 18: 343–346.
Medline
10.1002/(SICI)1097-0347(199607/08)18:4<343::AID-HED5>3.0.CO;2-Y CAS PubMed Web of Science® Google Scholar
- 66Motokura T, Bloom T, Kim HG, Juppner H, Ruderman JV, Kronenberg HM, Arnold A. A novel cyclin encoded by a bcl1-linked candidate oncogene. Nature 1991; 350: 512–515. Medline
- 67Sherr CJ. D-type cyclins. Trends Biochem Sci 1995; 20: 187–190. Medline
- 68Zwijsen RM, Klompmaker R, Wientjens EB, Kristel PM, van der Burg B, Michalides RJ. Cyclin D1 triggers autonomous growth of breast cancer cells by governing cell cycle exit. Mol Cell Biol 1996; 16: 2554–2560. Medline
- 69Meredith SD, Levine PA, Burns JA, Gaffey MJ, Boyd JC, Weiss LM, Erickson NL, Williams ME. Chromosome 11q13 amplification in head and neck squamous cell carcinoma. Association with poor prognosis. Arch Otolaryngol Head Neck Surg 1995; 121: 790–794. Medline
- 70Bellacosa A, Almadori G, Cavallo S, Cadoni G, Galli J, Ferrendina G, Scambia G, Neri G. Cyclin D1 gene amplification in human laryngeal squamous cell carcinomas: prognostic significance and clinical implications. Clin Cancer Res 1996; 2: 175–180. Medline
- 71Akervall JA, Michalides RJ, Mineta H, Balm A, Borg A, Dictor MR, Jin Y, Loftus B, Mertens F, Wennerberg JP. Amplification of cyclin D1 in squamous cell carcinoma of the head and neck and the prognostic value of chromosomal abnormalities and cyclin D1 overexpression. Cancer 1997; 79: 380–389.
Medline
10.1002/(SICI)1097-0142(19970115)79:2<380::AID-CNCR22>3.0.CO;2-W CAS PubMed Web of Science® Google Scholar
- 72Fortin A, Guerry M, Guerry R, Talbot M, Parise O, Schwaab G, Bosq J, Bourhis J, Salvatori P, Janot F, Busson P. Chromosome 11q13 gene amplifications in oral and oropharyngeal carcinomas: no correlation with subclinical lymph node invasion and disease recurrence. Clin Cancer Res 1997; 3: 1609–1614. Medline
- 73Kyomoto R, Kumazawa H, Toda Y, Sakaida N, Okamura A, Iwanaga M, Shintaku M, Yamashita T, Hiai H, Fukumoto M. Cyclin-D1-gene amplification is a more potent prognostic factor than its protein over-expression in human head-and-neck squamous-cell carcinoma. Int J Cancer 1997; 74: 576–581.
Medline
10.1002/(SICI)1097-0215(19971219)74:6<576::AID-IJC3>3.0.CO;2-R CAS PubMed Web of Science® Google Scholar
- 74Muller D, Millon R, Velten M, Bronner G, Jung G, Engelmann A, Flesch H, Eber M, Methlin G, Abecassis J. Amplification of 11q13 DNA markers in head and neck squamous cell carcinomas: correlation with clinical outcome. Eur J Cancer 1997; 33: 2203–2210. Medline
- 75Pignataro L, Pruneri G, Carboni N, Capaccio P, Cesana BM, Neri A, Buffa R. Clinical relevance of cyclin D1 protein overexpression in laryngeal squamous cell carcinoma. J Clin Oncol 1998; 16: 3069–3077. Medline
- 76Yoo S, Carter D, Turner BC, Sasaki CT, Wilson LD, Son YH, Glazer PM, Haffty BG. Prognostic significance of cyclin D1 protein levels in early stage larynx cancer treated with primary radiation. Proc ASCO 1998; 17: 397a.
- 77Turner B, Haffty B, Fritzell J, Peretz S, Carter D, Musgrove E, Sutherland R, Glazer P. Cyclin D1 expression influences cellular radiosensitivity in a human breast cancer cell line and correlates with ipsilateral breast tumor recurrence after lumpectomy and radiation therapy. Proc Am Assoc Cancer Res 1997; 38: 437.
- 78Ah-see KW, Cooke TG, Pickford IR, Soutar D, Balmain A. An allelotype of squamous carcinoma of the head and neck using microsatellite markers. Cancer Res 1994; 54: 1617–1621. Medline
- 79Li X, Lee NK, Ye YW, Waber PG, Schweitzer C, Cheng QC, Nisen PD. Allelic loss at chromosomes 3p, 8p, 13q, and 17p associated with poor prognosis in head and neck cancer. J Natl Cancer Inst 1994; 86: 1524–1529. Medline
- 80el-Naggar AK, Hurr K, Batsakis JG, Luna MA, Goep-fert H, Huff V. Sequential loss of heterozygosity at microsatellite motifs in preinvasive and invasive head and neck squamous carcinoma. Cancer Res 1995; 55: 2656–2659. Medline
- 81Ishwad CS, Ferrell RE, Rossie KN, Appel BN, Johnson JT, Myers EN, Law JC, Srivastava S, Gollin SM. Loss of heterozygosity of the short arm of chromosomes 3 and 9 in oral cancer. Int J Cancer 1996; 69: 1–4.
Medline
10.1002/(SICI)1097-0215(19960220)69:1<1::AID-IJC1>3.0.CO;2-8 CAS PubMed Web of Science® Google Scholar
- 82Scholnick SB, Haughey BH, Sunwoo JB, El-Mofty SK, Baty JD, Piccirillo JF, Zequeira MR. Chromosome 8 allelic loss and the outcome of patients with squamous cell carcinoma of the supraglottic larynx. J Natl Cancer Inst 1996; 88: 1676–1682. Medline
- 83Partridge M, Emilion G, Langdon JD. LOH at 3p correlates with a poor survival in oral squamous cell carcinoma. Br J Cancer 1996; 73: 366–371. Medline
- 84Maestro R, Piccinin S, Doglioni C, Gasparotto D, Vukosavljevic T, Sulfaro S, Barzan L, Boiocchi M. Chromosome 13q deletion mapping in head and neck squamous cell carcinomas: identification of two distinct regions of preferential loss. Cancer Res 1996; 56: 1146–1150. Medline
- 85Rowley H, Jones A, Spandidos D, Field J. Definition of a tumor suppressor gene locus on the short arm of chromosome 3 in squamous cell carcinoma of the head and neck by means of microsatellite markers. Arch Otolaryngol Head Neck Surg 1996; 122: 497–501. Medline
- 86Uzawa K, Suzuki H, Komiya A, Nakanishi H, Ogawara K, Tanzawa H, Sato K. Evidence for two distinct tumor-suppressor gene loci on the long arm of chromosome 11 in human oral cancer. Int J Cancer 1996; 67: 510–514.
Medline
10.1002/(SICI)1097-0215(19960807)67:4<510::AID-IJC8>3.0.CO;2-V CAS PubMed Web of Science® Google Scholar
- 87Bockmuhl U, Schwendel A, Dietel M, Petersen I. Distinct patterns of chromosomal alterations in high- and low-grade head and neck squamous cell carcinomas. Cancer Res 1996; 56: 5325–5329. Medline
- 88Jones JW, Raval JR, Beals TF, Worsham MJ, Van Dyke DL, Esclamado RM, Wolf GT, Bradford CR, Miller T, Carey TE. Frequent loss of heterozygosity on chromosome arm 18q in squamous cell carcinomas. Identification of 2 regions of loss–18q11.1-q12.3 and 18q21.1-q23. Arch Otolaryngol Head Neck Surg 1997; 123: 610–614. Medline
- 89Bockmuhl U, Petersen S, Schmidt S, Wolf G, Jahnke V, Dietel M, Petersen I. Patterns of chromosomal alterations in metastasizing and nonmetastasizing primary head and neck carcinomas. Cancer Res 1997; 57: 5213–5216. Medline
- 90Wang XL, Uzawa K, Miyakawa A, Shiiba M, Wata-nabe T, Sato T, Miya T, Yokoe H, Tanzawa H. Localization of a tumour-suppressor gene associated with human oral cancer of 7q31.1. Int J Cancer 1998; 75: 671–674.
Medline
10.1002/(SICI)1097-0215(19980302)75:5<671::AID-IJC2>3.0.CO;2-W CAS PubMed Web of Science® Google Scholar
- 91Joensu H. DNA flow cytometry in the prediction of survival and response to radiotherapy in head and neck cancer. A review. Acta Oncol 1990; 29: 513–516. Medline
- 92Stell PM. Ploidy in head and neck cancer: a review and meta-analysis. Clin Otolaryngol 1991; 16: 510–516. Medline
- 93Tytor M, Olofsson J, Ledin T, Brunk U, Klintenberg C. Squamous cell carcinoma of the oral cavity. A review of 176 cases with application of malignancy grading and DNA measurements. Clin Otolaryngol 1990; 15: 235–252. Medline
- 94Kearsley JH, Bryson G, Battistutta D, Collins RJ. Prognostic importance of cellular DNA content in head-and-neck squamous-cell cancers. A comparison of retrospective and prospective series. Int J Cancer 1991; 47: 31–37. Medline
- 95Rua S, Comino A, Fruttero A, Cera G, Semeria C, Lanzillotta L, Boffetta P. Relationship between histologic features, DNA flow cytometry, and clinical behavior of squamous cell carcinomas of the larynx. Cancer 1991; 67: 141–149.
Medline
10.1002/1097-0142(19910101)67:1<141::AID-CNCR2820670125>3.0.CO;2-E CAS PubMed Web of Science® Google Scholar
- 96Walter MA, Peters GE, Peiper SC. Predicting radioresistance in early glottic squamous cell carcinoma by DNA content. Ann Otol Rhinol Laryngol 1991; 100: 523–526. Medline
- 97Zatterstrom UK, Wennerberg J, Ewers SB, Willen R, Attewell R. Prognostic factors in head and neck cancer: histologic grading, DNA ploidy, and nodal status. Head Neck 1991; 13: 477–487. Medline
- 98Westerbeek HA, Mooi WJ, Hilgers FJ, Baris G, Begg AC, Balm AJ. Ploidy status and the response of T1 glottic carcinoma to radiotherapy. Clin Otolaryngol 1993; 18: 98–101. Medline
- 99Fu KK, Hammond E, Pajak TF, Clery M, Doggett RLS, Byhardt RW, McDonald S, Cooper JS. Flow cytometric quantification of the proliferation-associated nuclear antigen p105 and DNA content in advanced head and neck cancers: results of RTOG 91-08. Int J Radiat Oncol Biol Phys 1994; 29: 661–671. Medline
- 100Toffoli G, Franchin G, Barzan L, Cernigoi C, Carbone A, Sulfaro S, Franceschi S, Boiocchi M. Brief report: prognostic importance of cellular DNA content in T1-2 N0 laryngeal squamous cell carcinomas treated with radiotherapy. Laryngoscope 1995; 105: 649–652. Medline
- 101Welkoborsky HJ, Hinni M, Dienes HP, Mann WJ. Predicting recurrence and survival in patients with laryngeal cancer by means of DNA cytometry, tumor front grading, and proliferation markers. Ann Otol Rhinol Laryngol 1995; 104: 503–510. Medline
- 102Epp RA, Justice WM, Garcia FU, McGregor DH, Giri SP, Kimler BF. Retrospective DNA ploidy analysis by image and flow cytometry in head and neck cancer. Laryngoscope 1996; 106: 1306–1313. Medline
- 103Zackrisson B, Gustafsson H, Stenling R, Flygare P, Wilson GD. Predictive value of potential doubling time in head and neck cancer patients treated by conventional radiotherapy. Int J Radiat Oncol Biol Phys 1997; 38: 677–683. Medline
- 104Begg AC. The clinical status of Tpot as a predictor? Or why no tempest in the Tpot! Int J Radiat Oncol Biol Phys 1995; 12: 1539–1541.
- 105Begg AC, McNally NJ, Shrieve DC, Karcher H. A method to measure the duration of DNA synthesis and the potential doubling time from a single sample. Cytometry 1985; 6: 620–626. Medline
- 106Awwad H. Unconventional fractionation studies and Tpot correlation. Semin Radiat Oncol 1992; 2: 62–66.
10.1016/S1053-4296(05)80058-X Google Scholar
- 107Nylander K, Anneroth G, Gustafsson H, Roos G, Stenling R, Zackrisson B. Cell kinetics of head and neck squamous cell carcinomas. Prognostic implications. Acta Oncol 1994; 33: 23–28. Medline
- 108Cooke LD, Cooke TG, Forster G, Jones AS, Stell PM. Prospective evaluation of cell kinetics in head and neck squamous carcinoma: the relationship to tumor factors and survival. Br J Cancer 1994; 69: 717–720. Medline
- 109Wilson GD, Dische S, Saunders MI. Studies with bromodeoxyuridine in head and neck cancer and accelerated radiotherapy. Radiother Oncol 1995; 36: 189–197. Medline
- 110Corvo R, Giaretti W, Sanguineti G, Geido E, Orecchia R, Guenzi M, Margarino G, Bacigalupo A, Garaventa G, Barbieri M, Vitale V. In vivo cell kinetics in head and neck squamous cell carcinomas predicts local control and helps guide radiotherapy regimen. J Clin Oncol 1995; 13: 1843–1850. Medline
- 111Bourhis J, Dendale R, Hill C, Bosq J, Janot F, Attal P, Fortin A, Marandas P, Schwaab G, Wibault P, Malaise EP, Bobin S, Luboinski B, Eschwege F, Wilson G. Potential doubling time and clinical outcome in head and neck squamous cell carcinoma treated with 70 GY in 7 weeks. Int J Radiat Oncol Biol Phys 1996; 35: 471–476. Medline
- 112Hoyer M, Jorgensen K, Bundgaard T, Johansen LV, Bentzen SM, Overgaard M, Hansen O, Sogaard H, Overgaard J. Lack of predictive value of potential doubling time and iododeoxyuridine labelling index in radiotherapy of squamous cell carcinoma of the head and neck. Radiother Oncol 1998; 46: 147–155. Medline
- 113Begg AC, Hofland I, Moonen L, Bartelink H, Schraub S, Bontemps P, Le Fur R, Van Den Bogaert W, Caspers R, Van Glabbeke M, Horiot JC. The predictive value of cell kinetic measurements in a European trial of accelerated fractionation in advanced head and neck tumors: an interim report. Int J Radiat Oncol Biol Phys 1990; 19: 1449–1453. Medline
- 114Begg AC, Hofland I, Van Glabbeke M, Bartelink H, Horiot JC. Predictive value of potential doubling time for radiotherapy of head and neck tumor patients: results from the EORTC cooperative trial 22851. Semin Radiat Oncol 1992; 2: 22–25.
10.1016/S1053-4296(05)80046-3 Google Scholar
- 115Struikmans H, Rutgers DH, Hordijk GJ, Slootweg PJ, van der Tweel I, Batterman JJ. Interrelationships of DNA-ploidy and cell proliferation markers with T-stage and N-stage in primary laryngeal tumors. Int J Radiat Oncol Biol Phys 1998; 40: 303–308. Medline
- 116Grandis JR, Melhem M, Gooding W, Day R, Holst V, Wagener M, Drenning S, Tweardy D. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998; 90: 824–832. Medline
- 117Dassonville O, Formento JL, Francoual M, Ramaioli A, Santini J, Schneider M, Demard F, Milano G. Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol 1993; 11: 1873–1878. Medline
- 118Wen QH, Miwa T, Yoshizaki T, Nagayama I, Furukawa M, Nishijima H. Prognostic value of EGFR and TGF-alpha in early laryngeal cancer treated with radiotherapy. Laryngoscope 1996; 106: 884–885. Medline
- 119Maurizi M, Almadori G, Ferrandina G, Distefano M, Romanini M, Cadoni G, Benedetti-Panici P, Pludetti G, Scambia G, Mancuso S. Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma. Br J Cancer 1996; 74: 1253–1257. Medline
- 120Lee CS, Redshaw A, Boag G. TGF-alpha immunoreactivity in laryngeal carcinoma: lack of prognostic value and correlation to egf-receptor expression. Aus NZ J Surg 1996; 66: 464–468.
- 121Issing W, Liebich C, Toham P, Wustrow U, Ullrich A, Coexpression of epidermal growth factor receptor and TGF-alpha and survival in upper aerodigestive tract cancer. Anticancer Res 1996; 16: 283–288. Medline
- 122Maurizi M, Scambia G, Benedetti-Panici P, Ferrandina G, Almadori G, Paludetti G, DeVincenzo R, Distefano M, Brinchi D, Candoi G, Mancuso S. EGF receptor expression in primary laryngeal cancer: correlation with clinico-pathological features and prognostic significance. Int J Cancer 1992; 52: 862–866. Medline
- 123Santini J, Formento J, Francoual M, Milano G, Schneider M, Dassonville D, Demard F. Characterization, quantification and potential clinical value of the epidermal growth factor receptor in head and neck squamous cell carcinomas. Head Neck 1991; 13: 132–139. Medline
- 124Sheriden M, O'Dwyer T, Seymour C, Mothersill C, Potential indicators of radiosensitivity in squamous cell carcinoma of the head and neck. Radiat Oncol Invest 1997; 5: 180–186.
10.1002/(SICI)1520-6823(1997)5:4<180::AID-ROI3>3.0.CO;2-U Google Scholar
- 125Schmidt-Ullrich R, Mikkelsen R, Dent P, Todd D, Valeri K, Kavanasgh B, Contessa J, Rotter W, Chen P. Radiation induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosin phosphorylation. Oncogene 1997; 15: 1191–1197. Medline
- 126Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 1999; 59; 1935–1940. Medline
- 127Gasparini G, Bavilacqua P, Bonoldi E, Testolin A, Galassi A, Verderio P, Boracchi P, Guglielmi RB, Pezzella F. Predictive and prognostic markers in a series of patients with head and neck squamous cell invasive carcinoma treated with concurrent chemoradiation therapy. Clin Cancer Res 1995; 1: 1375–1383. Medline
- 128Wilson GD, Grover R, Richman PI, Daley FM, Saunders MI, Dische S. BCL-2 expression correlates with favourable outcome in head and neck cancer treated by accelerated radiotherapy. Anticancer Res 1996; 16: 2403–2408. Medline
- 129Pena JC, Thompson CB, Recant W, Vokes EE, Rudin CM. Bcl-xL and Bcl-2 expression in squamous cell carcinoma of the head and neck. Cancer 1999; 85: 164–170.
Medline
10.1002/(SICI)1097-0142(19990101)85:1<164::AID-CNCR23>3.0.CO;2-Q CAS PubMed Web of Science® Google Scholar
- 130Whistler LC, Wood NB, Caldarelli DD, Hutchinson JC, Panje WR, Friedman M, Preisler HD, Leurgans S, Nowak J, Coon JS. Regulators of proliferation and apoptosis in carcinoma of the larynx. Laryngoscope 1998; 108: 630–638. Medline
- 131Friedman M, Grey P, Venkatesan TK, Bloch I, Chawla P, Caldarelli DD, Coon JS. Prognostic significance of Bcl-2 expression in localized squamous cell carcinoma of the head and neck. Ann Otol Rhinol Laryngol 1997; 106: 445–450. Medline
- 132Costa A, Licitra L, Veneroni S, Daidone MG, Grandi C, Cavina R, Molinari R, Silvestrini R. Biological markers as indicators of pathological response to primary chemotherapy in oral-cavity cancers. Int J Cancer 1998; 79: 619–623.
Medline
10.1002/(SICI)1097-0215(19981218)79:6<619::AID-IJC11>3.0.CO;2-A CAS PubMed Web of Science® Google Scholar
- 133Knerer B, Formanek M, Schickinger B, Martinek H, Kornfehl J. Different KGF expression in squamous cell carcinomas of the head and neck and in normal mucosa. Acta Otolaryngol 1998; 118: 438–442.
- 134Ross J, Fletcher J. The Her-2 neu oncogene in breast cancer: prognostic factor, predictive factor and target for therapy. Stem Cells 1998; 16: 413–428. Medline